Incannex Healthcare (NASDAQ: IXHL)

Last close As at 28/03/2024

USD0.97

−0.11 (−10.19%)

Market capitalisation

62m

Latest Insights

View More

Healthcare | Flash note

Incannex Healthcare — On the road to psychotherapy clinics

Healthcare | Flash note

Incannex Healthcare — On to Phase II for IHL-675A

Healthcare | Flash note

Incannex Healthcare — A clinically active quarter

incannex07

Sector

Healthcare

Balance Sheet

Forecast net cash (A$m)

29.6

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (3.0) (36.3) (76.2)
Relative (12.3) (38.0) (79.3)
52 week high/low US$4.0/US$0.8

Financials

Incannex, an Australian-based biotech, has several active studies investigating cannabinoid combinations for a range of conditions, but is also focused on assessing psilocybin for the treatment of generalized anxiety disorder (GAD). In the psychedelics space, Incannex’s ongoing Phase II trial (Psi-GAD) received an encouraging interim review in March 2023, and we see the completion of the study in Q4 CY23 as a significant catalyst. Incannex has also recently announced developments in its psychedelic clinics business through its subsidiary Clarion Clinics Group. In this note, we provide an overview of psychedelics as therapeutics, the GAD market, and Incannex’s position in the emerging field of psychedelic-based therapies. Our valuation for Incannex stands at US$750.7m or US$11.83 per ADR (vs US$745.8m or US$11.75 per ADR previously).

Y/E Jun Revenue (A$m) EBITDA (A$m) PBT (A$m) EPS (fd) (c) P/E (x) P/CF (x)
2021A 2.0 N/A (8.2) (0.83) N/A N/A
2022A 0.8 N/A (14.9) (1.25) N/A N/A
2023E 0.1 N/A (20.7) (1.43) N/A N/A
2024E 0.1 N/A (33.4) (2.10) N/A N/A

Further insights

insight

Healthcare

Incannex Healthcare: Is life better on Nasdaq?

Incannex mother and child

insight

Healthcare

Incannex Healthcare: Data opens path to treat anxiety

insight

Healthcare

Healthcare Week 2023

Analyst of the week

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Read latest

Thematics

thematic

Healthcare

Deutsches Eigenkapitalforum (EKF) 2023 healthcare

volition01

thematic

Healthcare

VolitionRx – Decoding the DNA of cancer 

thematic

Healthcare

ASCO 2023 key takeaways

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free